Safe Harbor Statement

Similar documents
Safe Harbor Statement

Safe Harbor Statement

Global Spine Market Report

Business Review Deutsche Bank Conference May 4, Gary Pruden Company Group Chairman Worldwide Franchise Chairman Ethicon

Cautions Concerning Forward-looking Statements

NuVasive, Inc. Acquisition of Ellipse Technologies, Inc. January 5, 2016

Deutsche Bank Health Care Conference

Exactech Investor Update

Jefferies London Healthcare Conference Julie Brown, CFO

Safe Harbor Statement

Exane BNP Paribas Conference 10 May 2010

RTIX Investor Presentation

33rd Annual J.P. Morgan Healthcare Conference Olivier Bohuon, CEO

Canaccord Genuity Musculoskeletal Conference San Francisco, CA February 7, Integra LifeSciences Corporation. All rights reserved.

Special Issue. Mesoblast Limited

STRYKER ANALYST MEETING. September 2014

Anika Therapeutics, Inc.

Lombard Medical, Inc. (NASDAQ:EVAR) June 2016

MEDICATION DELIVERY. David Ferguson GM, Medication Delivery. May 21, 2018

CEO s Round Table June

Jefferies Healthcare Conference

Edwards Lifesciences

JP Morgan Healthcare Conference. 11 January 2010

The Leader in the Science of Heart Valves and Hemodynamic Monitoring

Anika Therapeutics, Inc.

psivida Transforms into Commercial Stage Specialty BioPharmaceutical Company ASCRS April 12, 2018 NASDAQ: EYPT

Investor Presentation. November 26, 2013

For personal use only

NASDAQ: EYES. Investor Presentation

JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE JUNE 3, 2015 NACHUM HOMI SHAMIR PRESIDENT AND CHIEF EXECUTIVE OFFICER

The Interim Results of smith&nephew for 2003: reduced pain, faster recovery, more cost-effective treatments. Sales growth was 11% and we helped

37 th Annual JP Morgan Healthcare Conference

Wright Medical Group, Inc.

The New SEPTEMBER 2018 MARCH

Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device

Outpatient Spine Surgery The Next Five Years Richard Wohns,, M.D., JD, MBA Neospine,, Puget Sound Region, Washington. Disclosures.

2 stryker 2010 annual review. Dear Shareholders,

psivida Corp PSDV June 2016

AMGEN ASTELLAS AND ASTELLAS ANNOUNCE SUBMISSION OF APPLICATION FOR INVESTIGATIONAL OSTEOPOROSIS MEDICATION ROMOSOZUMAB IN JAPAN

aap Implantate AG Corporate Presentation German Equity Forum 2018 Bruke Seyoum Alemu, CEO Marek Hahn, CFO

Louise Mehrotra. Vice President Investor Relations

SCOPE OF ACCREDITATION TO ISO/IEC 17025:2005. ELEMENT CINCINNATI 3701 Port Union Road Fairfield, Ohio Justin Riebesel Phone:

France Spinal Surgery Procedures Outlook to 2020

Strategic Business Update November 3, 2014 Conference Call. Spin-off of the Spine Business and Portfolio Alignment into Two Global Divisions

The Ultimate Guide To STEM CELL THERAPY. for Joint Disorders

INVESTOR PRESENTATION. February 2012

OSCILLATING SAW BLADES PAT. PENDING SPEZIAL TOOTHING

Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q

our history Codman Instrument Portfolio

Pluristem Issues Letter to Shareholders

J.P. Morgan Health Care Conference

Overview and Progress Update: Medicare Performance Initiative (MPI)

Adult Stem Cells for Chronic Pain. Dr. John Hughes, DO January 24 th, 2018

Changing the Trajectory of Atrial Fibrillation and Stroke Shlomi Nachman

Acquisition of Polymer Technology Group

Capital Market Day June 12, 2012

ASX Small to Mid Caps Conference Singapore. May 27 th, 2010

Case No COMP/M SMITH & NEPHEW / CENTERPULSE. REGULATION (EEC) No 4064/89 MERGER PROCEDURE. Article 6(1)(b) NON-OPPOSITION Date: 27/05/2003

New Cardinal Health (Post-Spin)

Raymond James 34th Annual Institutional Investors Conference

For personal use only

EvaluateMedTech has used a number of sources within the site to develop a 4-level classification tree based on the FDA approvals process.

Medical Engineering (Biomedical Engineering, Clinical Engineering, Bioengineering) Medical Materials Science (Biomaterials) Dental Materials Science

Investor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER

The Future of Consumer Health Care

SIMPLICITY OF INTUITIVE CONTROL JOIN THE MOVEMENT, DEMOCRATIZE MIS. flexdex.com

Hill-Rom: Acquiring Mortara Instrument Complementary Combination Strengthens Clinical Focus on Diagnostic Cardiology and Patient Monitoring

The technologies behind next-gen neuromodulation devices

OTCQB: KSHB NICK KOVACEVICH OCTOBER 2017

AmerisourceBergen. J.P. Morgan Healthcare Conference. Steve Collis, Chairman, President & CEO Tim Guttman, EVP & CFO.

FORWARD LOOKING STATEMENT

OTCQB: KSHB NICK KOVACEVICH JULY 2017

Jefferies TMT Conference

REDEFINING ROBOTIC SURGERY SIMPLICITY OF INTUITIVE CONTROL. flexdex.com

Annual General Meeting Fresenius SE Welcome. May 12, 2010

Investor Presentation

Global Robotic Surgery Market Report

Investor Presentation December NYSE American: IEC

INDUSTRY OVERVIEW SOURCE OF INFORMATION

R1 to Acquire Intermedix and Selected as RCM Services Provider for Ascension Physician Business

Precision in fixation

Safe Harbor Statement

Corporate Strategy Meeting For the Fiscal Year ending March 31, 2014

Plumbing Products. Richard O Reagan / Group President, Global Plumbing

Cautions Concerning Forward-looking Statements

Proven 1-4, Safe Performance. Product overview

One Surgeon. One Patient. FLH /11

Cervical Total Disc Replacement

Let s Talk. Science... The Science of: > > > Motion13. Wear1. Triathlon. Knee System

Teva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference. Kåre Schultz President and CEO January 7, 2019

Jefferies 2017 Global Healthcare Conference. June 7, 2017

Standards and Regulatory Considerations for Orthopaedic Implants

WILLIAM BLAIR GROWTH STOCK CONFERENCE. June 14, 2017

Todd M. Pope President & CEO. JP Morgan Healthcare Conference January 8, 2018

Precision Vascular Robotics. Corindus Vascular Robotics (CVRS) November 2017

PerkinElmer, Inc. JP Morgan Global Healthcare Conference. Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH

Jefferies 2018 Global Healthcare Conference. June 7, 2018

Health Care Business Group

Jefferies 2015 Global Healthcare Conference June 3, 2015

More than surface deep

Transcription:

Safe Harbor Statement This presentation may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company s expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 to the Company s Annual Report on Form 10-K for the fiscal year ended January 3, 2010. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from the Company. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.

Michael Mahoney Company Group Chairman Worldwide Franchise Chairman DePuy

DePuy Franchise Orthopaedics Spine Sports Medicine Neurosurgery

We compete in very large markets with consistent growth rates and tremendous untapped potential to keep people moving DePuy is a market leader with solid market momentum and strong financial performance DePuy will grow by leading in core markets, innovating into new growth segments and expanding globally with a focus on emerging markets

Worldwide Market Size 2009 Market: $38.6B 6.4% Growth 2014 Market: $53.6B 6.8% CAGR Other ** $3.1B Neuro* $4.8B Hips $6.4B Other ** $4.1B Neuro* $7.4B Hips $8.1B Sports $3.9B Knees $7.2B Sports $5.8B Knees $9.6B Spine $8.7B Trauma $4.5B Spine $12.2B Trauma $6.4B * Includes neuromodulation ** Includes extremities, bone cement, biologics, etc. Source: Internal Estimates Note: All figures operational

2009 DePuy Growth Exceeds Market Growth Faster Than Market in Most Segments OPERATIONAL DEPUY GROWTH OPERATIONAL MARKET GROWTH (INTERNAL ESTIMATE) Hips 7.9% 3.5% Knees 4.9% 4.3% Trauma & Extremities 10.1% 7.9% Spine 10.9% 8.8% Sports 12.0% 8.5% Neuro 4.2% 6.6%* Total 7.5% 6.4% * Includes neuromodulation Source: Internal Estimates Note: All figures operational Above Market Below Market

DePuy Franchise SALES YE 2009 GROWTH 2009 CAGR 2004-2009 WW MARKET POSITION 2009* $5.4B 7.5% 8.3% #1 Growth Strategies Win in core markets Lead and innovate in new growth segments Drive operational effectiveness to fuel growth Accelerate global expansion Strengthen franchise capabilities * Internal Estimate Note: All growth figures operational

Hip Replacement SALES GROWTH 2009 WW MARKET POSITION 2009* WW MARKET 2009-2014 CAGR* TOTAL WW MARKET REVENUE 2014* 7.9% #2 5.0% $8.1B Growth Strategies Extend leadership in high performance portfolio Improve surgical efficiency Strengthen position in revisions * Internal Estimate Note: All figures operational

Hip Solutions: Leadership in High Performance Pinnacle Widest range of solutions Unparalleled clinical heritage High stability with low wear Pinnacle CoMplete Expected first ceramic-on-metal in U.S. (pending FDA approval) Durability, stability for active patient Enhanced wear characteristics Metal on Poly Available WW Ceramic on Poly Available WW Metal on Metal Available WW Ceramic on Metal Available O.U.S., Pending FDA Approval Ceramic on Ceramic Available O.U.S., Pending FDA Approval

High Performance Solutions: Finsbury High performance, large diameter hip bearings DeltaMotion Proprietary ceramic-on-ceramic O.U.S. Stability, range of motion Reduced risk of dislocation, low wear Adept Hip System for resurfacing Excellent clinical heritage

Surgical Efficiency Solutions: Anterior Approach Unique bone-preserving stem Enhances operating room efficiency Less pain, quick recovery Driven by excellence in professional education

Hip Revision Solutions Strengthening position in fast growing segment New platform launches Corail Revision Gription TF ReClaim Unparalleled range of hip options

Knee Replacement SALES GROWTH 2009 WW MARKET POSITION 2009* WW MARKET 2009-2014 CAGR* TOTAL WW MARKET REVENUE 2014* 4.9% #2 6.0% $9.6B Growth Strategies Drive high performance portfolio Improve surgical efficiency Reinforce leadership in knee revisions * Internal Estimate Note: All figures operational

High Performance Knee Solutions Sigma High Performance Platform High performance instrumentation Fixed & mobile bearing Sigma High Performance Partial Knee Replace only affected part of knee Natural motion, quick recovery AOX poly: Pending FDA approval

Surgical Efficiency Solutions TruMatch : Patient-specific instruments Improves operating room productivity 15% reduction in OR time 52% reduction in prep time Offers unique advantages CT scan Metal saw and pin captures

Knee Revision Solutions Strengthen leadership in high growth segment Function with wear resistance Only rotating platform design Stability Wide range of options Excellence in professional education

Spine SALES GROWTH 2009 WW MARKET POSITION 2009* WW MARKET 2009-2014 CAGR* TOTAL WW MARKET REVENUE 2014* 10.9% #2 7.0% $12.2B Growth Strategies Win in degenerative spinal care Strengthen leadership in deformity Accelerate growth in vertebral body augmentation (VBA) * Internal Estimate Note: All figures operational

Win in Degenerative VIPER 2 minimally invasive solutions Single solution for thoracic to lumbar spine Used for both simple and complex cases New implant options Introducing VIPER 3D System in Q3 Brings MIS solutions to complex surgery Open surgery results, percutaneous approach

Win in Degenerative COUGAR LS New Lateral Approach Platform Excellent visualization and access Simplified cage insertion Complement to VIPER 2 Neuro-monitoring enabled Uses standard hospital equipment Hospital cost savings

Strengthen Leadership in Deformity EXPEDIUM Spine System Most sophisticated deformity system New favored angle screw facilitates all deformity correction maneuvers in one implant New universal connector set enables seamless revision constructs

DePuy Pipeline Highlights Pending CoMplete * Acetabular Hip System GRIPTION TF (TIFOAM)* Hip and Knee AOX Poly for Sigma and LCS Affixus Hip Fracture Nail* MEDSTREAM * Programmable Pump 2009-2010 2010 2011 2012 Approved/Cleared/Launched Planned Submissions Planned Submissions Planned Submissions ASPHERE * RECLAIM Hip Revision Next Generation Knee System DeltaMotion Hip System* Contoured Metal Heads Next Generation DVR Bone Preserving Hip Stem Hip Bearings TruMatch * Wrist Plate* Personalized Solutions New Poly Hip Bearings Hip Resurfacing System Shoulder Fracture Platform Sigma CR150* DVR Express Next Generation Hip System Mobile Bearing CONFIDENCE Spinal Cement System LX TLIF Cage WW Screw Next Generation Shoulder A.L.P.S. System Modules* (Anatomic Fibula, Anatomic Elbow, EXPEDIUM LX Platelet Rich Plasma System CAIS Cartilage Regeneration Proximal Tibia) VIPER LX COUGAR LS Lateral Cage TLIF Cage ScoliScore AIS Prognostic Test* VaprVue & Coolpulse 90 GRYPHON BR ANCHOR NEXTRA System ORBIT GALAXY Detachable Embolic Coil* * U.S. submission only. This information is accurate as of the date hereof to the best of the Company s knowledge. Johnson & Johnson assumes no obligation to update this information. Selected Highlights as of 6/3/10

Accelerate Global Expansion Japan Strengthen portfolio Emerging market growth Increase professional education Develop segmented portfolio Expand manufacturing, R&D

We compete in very large markets with consistent growth rates and tremendous untapped potential to keep people moving DePuy is a market leader with solid market momentum and strong financial performance DePuy will grow by leading in core markets, innovating into new growth segments and expanding globally with a focus on emerging markets

DePuy Appendix

Sports Medicine SALES GROWTH 2009 WW MARKET POSITION 2009* WW MARKET 2009-2014 CAGR* TOTAL WW MARKET REVENUE 2014* 12.0% #3 8.0% $5.8B Growth Strategies Drive innovative arthroscopy platforms Expand minimally invasive office-based technologies Advance biologic solutions for cartilage repair * Internal Estimate Note: All figures operational

Trauma SALES GROWTH 2009 WW MARKET POSITION 2009* WW MARKET 2009-2014 CAGR* TOTAL WW MARKET REVENUE 2014* 8.9% #4 7.0% $6.4B Growth Strategies Launch Affixus Hip Fracture Platform Continue expansion of A.L.P.S. Locked Plating portfolio Register key brands in targeted Asian markets * Internal Estimate Note: All figures operational

Extremities SALES GROWTH 2009 WW MARKET POSITION 2009* WW MARKET 2009-2014 CAGR* TOTAL WW MARKET REVENUE 2014* 11.8% #1 11.0% $1.3B Growth Strategies Enhance market-leading shoulder portfolio Shoulder fracture platform Unique glenoid solutions Bone conservation technologies * Internal Estimate Note: All figures operational

Neuro SALES GROWTH 2009 WW MARKET POSITION 2009* WW MARKET 2009-2014 CAGR* TOTAL WW MARKET REVENUE 2014* 4.2% #3 9.0% ** $7.4B ** Growth Strategies Establish leadership in neurovascular Expand into neuromodulation drug delivery systems Leverage foundation in neurosurgery to expand into emerging markets * Internal Estimate ** Includes neuromodulation Note: All figures operational